Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q2 FY2021 Earnings Presentation
18 slides from Alkem Laboratories's earnings presentation, Nov 6, 2020
Slide 1: Cover letter to stock exchanges
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Pare! (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 06 th November, 2020 The Co
Slide 2: Press Release: Alkem reports Q2FY21 and H1FY21 Results
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Press Release Alkem reports
Slide 3: Operational Highlights: India Business
ALKEM LABORATORIES LTD. <8> ALKEM Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • GIN: L00305MH1973PLC174201 Operational Highlights Indi
Slide 4: US and Other International Sales; R&D Investments
ALKEM LABORATORIES LTD. <8> ALKEM Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email : contact@alkem.com • Website : www.alkemlabs.com • CIN : L00305MH1973PLC174201 • US sales for the quart
Slide 5: Q2FY21 and H1FY21 Conference Call details
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Q2FY21 and H1FY21 Conferenc
Slide 6: Alkem Laboratories Ltd. Q2FY21
<a> ALKEM Alkem Laboratories Ltd. Investor Presentation Q2FY21 – November 6, 2020 ••• ~I!!!!~ .... ~ ~rl I ••••
Slide 7: Safe Harbor Statement
<a> ALKEM Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assump
Slide 8: Key Highlights of Q2FY21 and H1FY21
<a> Key Highlights of Q2FY21 and H1FY21 ALKEM Recovery in India business, while International business continues its growth momentum • Revenue from Operations grew by 4.4% YoY during the quarter, accompanied by significant expansion in EBITDA margin to 25.4% compared to 20.0% in Q2FY20 • Profit Afte
Slide 9: Key Financial Highlights – Q2FY21 (Consolidated)
<a> Key Financial Highlights – Q2FY21 (Consolidated) ALKEM All figures in ₹ mn Revenue from Operations India sales ! I YoY: 0.5% 23,628 ! 15,503 15,574 22,640 I ! l I ! I lI ! Q2FY20 Q2FY21 I I ! International sales l I I 7,790 ! 6,691 \ I ! I Q2FY20 Q2FY21 ! l! ! : Q2FY20 Q2FY21
Slide 10: Key Financial Highlights – Q2FY21 (Consolidated)
<a> Key Financial Highlights – Q2FY21 (Consolidated) ALKEM All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 13,597 - -- 14,289 4,526 6,005 60.1% 60.5% ! 20.0% 25.4% I ! ' Q2FY20 Q2FY21 I Q2FY20 Q2FY21 I ------------------t----------------- 1 ------------------------- PBT (b
Slide 11: Key Financial Highlights – H1FY21 (Consolidated)
<a> Key Financial Highlights – H1FY21 (Consolidated) ALKEM Particulars (₹ mn) H1FY21 H1FY20 YoY growth Revenue from Operations 43,663 41,135 6.1% Gross Profit 26,985 24,974 8.1% Gross Profit margin 61.8% 60.7% EBITDA 11,337 7,171 58.1% EBITDA margin 26.0% 17.4% PBT 10,405 6,199 67.9% PBT margin 23.8
Slide 12: India Business
<a> India Business ALKEM India Business: Q2FY21 Sales of ₹ 15,574 million (0.5% YoY growth) • India sales contributed 66.7% to total sales in Q2FY21 • The Company witnessed recovery in its India sales in Q2FY21 as the Government announced multiple rounds of unlocking • During the quarter, the Compan
Slide 13: Secondary Sales Performance
<a> Secondary Sales Performance ALKEM Company’s India business witnessed a recovery in Q2FY21 vs Q1FY21 -, Alkem’s YoY Alkem’s YoY Alkem’s YoY Therapy segment growth in growth in growth in 6,000 I ~ 5,620 Q1FY21 Q2FY21 H1FY21 Alkem’s monthly secondary sales (₹ mn) n Anti-infectives -22.1% -12.2% -16
Slide 14: US Business
<a> US Business ALKEM US Business: Q2FY21 Sales of ₹ 6,258 million (18.6% YoY growth) • US sales contributed 26.8% to total sales in Q2FY21 • Growth in US dollar terms was 12% YoY mainly driven by new product launches • In Q2FY21, the Company filed 1 ANDA with the US FDA and received 4 approvals (in
Slide 15: US Business: EIR for all six facilities inspected by US FDA
<a> US Business ALKEM EIR for all the six facilities inspected by the US FDA Facility Capability Last inspection Status post last inspection St. Louis (US) Formulation February 2020 EIR# received in May 2020 Baddi (India) Formulation February 2020 EIR# received in March 2020 Daman (India) Formulatio
Slide 16: Other International Business
<a> Other International Business ALKEM Other International Business: Q2FY21 Sales of ₹ 1,532 million (8.3% YoY growth) • Other International Market sales contributed 6.6% to total sales in Q2FY21 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Chile
Slide 17: Latest Shareholding Pattern
<a> Latest Shareholding Pattern ALKEM Shareholding pattern as on September 30, 2020 Non-Institution, 20.76% Promoter & Promoter Group, Institution, 62.43% 16.81% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Publ
Slide 18: Thank You
<a> ALKEM Thank You For further information or queries please contact Gagan Borana Investor Relations – Alkem Laboratories Ltd. Tel: +91 22 3982 9960 E-mail: gagan.borana@alkem.com